Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Stabilized enzymes or enzymes complexed with nonenzyme
Reexamination Certificate
2011-03-29
2011-03-29
Monshipouri, Maryam (Department: 1656)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Stabilized enzymes or enzymes complexed with nonenzyme
C530S350000
Reexamination Certificate
active
07914781
ABSTRACT:
The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol.
REFERENCES:
patent: 5596091 (1997-01-01), Switzer
patent: 6281199 (2001-08-01), Gupta
patent: 7108851 (2006-09-01), Higuchi et al.
patent: 7335638 (2008-02-01), Higuchi
patent: 7674832 (2010-03-01), Higuchi
patent: 7732410 (2010-06-01), Higuchi
patent: 2003/0124109 (2003-07-01), Higuchi et al.
patent: 2005/0142116 (2005-06-01), Higuchi
patent: 2009/0068167 (2009-03-01), Higuchi
patent: WO/02/02050 (2002-01-01), None
patent: WO/03/082324 (2003-10-01), None
patent: WO/2006/034560 (2006-04-01), None
U.S. Appl. No. 10/086,913, filed Mar. 1, 2002.
U.S. Appl. No. 10/952,003, filed Sep. 28, 2004.
U.S. Appl. No. 12/033,204, filed Feb. 19, 2008.
U.S. Appl. No. 12/033,193, filed Feb. 18, 2008.
U.S. Appl. No. 12/717,013, filed Mar. 3, 2010.
U.S. Appl. No. 10/086,913, Mar. 21, 2006 Notice of Allowance.
U.S. Appl. No. 10/086,913, Nov. 9, 2005 Response to Final Office Action.
U.S. Appl. No. 10/086,913, Oct. 24, 2005 Notice of Allowance.
U.S. Appl. No. 10/086,913, Jul. 29, 2005 Response to Non-Final Office Action.
U.S. Appl. No. 10/086,913, Jan. 27, 2005 Non-Final Office Action.
U.S. Appl. No. 10/952,003, Oct. 1, 2007 Notice of Allowance.
U.S. Appl. No. 10/952,003, Sep. 7, 2007 Request for Continued Examination.
U.S. Appl. No. 10/952,003, Jul. 30, 2007 Notice of Allowance.
U.S. Appl. No. 10/952,003, Apr. 23, 2007 Response to Non-Final Office Action.
U.S. Appl. No. 10/952,003, Jan. 23, 2007 Non-Final Office Action.
U.S. Appl. No. 12/033,204, Oct. 20, 2009 Notice of Allowance.
U.S. Appl. No. 12/033,193, Jan. 8, 2010 Notice of Allowance.
U.S. Appl. No. 12/717,013, Jun. 21, 2010 Notice of Allowance.
Agusti, et al., 1997, “The trans-sialidase of Trypanosome cruzi is anchored by two different lipids,” Glycobiology, vol. 7, No. 6: p. 731-735.
Aiello, et al., 2002, “A possible role for complement in the pathogenesis of chronic chagasic cardiomyopathy,” Journal of Pathology, vol. 197: p. 224-229.
Akira et al., “Toll-like receptors: critical proteins linking innate and acquired immunity,” Nature Immunol. 2:675-680(2001).
Amaya, et al., 2004, “Structural Insights into the catalytic mechanism of Trypanosoma cruzi trans-sialidase,” Structure, vol. 12: p. 775-784.
Amend et al., “Energetics of overall metabolic reactions of thermophilic and hyperthermophilic archaea and bacteria,” F.E.M.S. Microbiol. Rev. 25: 175-243 (2001).
Baseman, et al., 1982, “Sialic acid residues mediate Mycoplasma pneumoniae attachment to human and sheep erythrocytes,” Infect. Immun., vol. 38, No. 1: p. 389-391.
Berbec, et al., 1999, “Total serum sialic acid concentration as a supporting marker of malignancy in ovarian neoplasia,” Eur. J. Gynaecol On Col., vol. 20, No. 5-6: p. 389-392.
Blanchard, et al., 1994, “AIDS-associated mycoplasmas,” Annu. Rev. Microbiol., vol. 48: p. 687-712.
Bredt, et al., 1982, “Adherence of mycoplasmas: phenomena and possible role in the pathogenesis of disease,” Infection, vol. 10, No. 3: p. 199-201.
Briones, et al., 1993, “Trypanosoma cruzi trans-sialidase homologue,” Accession No. AAC98544, GI:624626, 736 aa.
Buscaglia, et al., 1998, “The repetitive domain of Trypanosome cruzi trans-sialidase enhances the immune response against the catalytic domain,” J. Infect. Dis., vol. 177, No. 2: p. 431-436.
Buscaglia, et al., 1999, “Tandem amino acid repeats from Trypanosoma cruzi shed antigens increase the half-life of proteins in blood,” Blood, vol. 93: p. 2025-2032.
Buschiazzo, et al., 1996, “Medium scale production and purification to homogeneity of a recombinant trans-sialidase from Trypanosoma cruzi,” Cell Mol. Biol., vol. 42: p. 703-710.
Buschiazzo, et al., 2002, “The Crystal Structure and Mode of Action of Trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis,” Molecular Cell, vol. 10: p. 757-758.
Campetella, et al., 1994, “A recombinant Trypanosoma cruzi trans-sialidase lacking the amino acid repeats retains the enzymatic activity,” Mol. Biochem. Parasitol., vol. 64: p. 337-340.
Chandler, et al., 1982, “Mycoplasma pneumoniae attachment: competitive inhibition by mycoplasmal binding component and by sialic acid-containing glycoconjugates,” Infect. Immun., vol. 38, No. 2: p. 598-603.
Chen et al., “Apoptosis of hepatoma cells SMMC-7721 induced by Ginkgo biloba seed polysaccharide,” World J. Gastroenterol. 8: 832-6 (2002).
Chen et al., 1986, “Carditis associated with Mycoplasma pneumoniae infection,” Am. J. Dis. Child., vol. 140: p. 471-472.
Clyde et al., “Tropism for Mycoplasma gallisepticum for arterial walls,” Proc. Natl. Acad. Sci. U.S.A. 70: 1545-1549 (1973).
Cole, 1997 “Mycoplasma interactions with the immune system: implications for disease pathology,” http://www.compkarori.com/arthritis/pi16002.htm.
Cole, 1999, “Mycoplasma-induced arthritis in animals: relevance to understanding the etiologies of the human rheumatic diseases,” Rev. Rhum. Engl. Ed. 66, 1Suppl: p. 45S-49S.
Collier and Clyde, “Relationships between M. pneumoniae and human respiratory epithelium,” Infect. Immun. 3:694-701 (1971).
Cremona, et al., 1995, “A single tyrosine differentiates active and inactive Trypanosome cruzi trans-sialidase,” Gene, vol. 160: p. 123-128.
Cremona, et al., 1996, “Effect of primary structure modifications in Trypanosoma cruzi neuramindase trans-sialidase activities,” Cell. Mol. Biol., vol. 42: p. 697-702.
Dallo, et al., 2000, “Intracellular DNA replication and long term survival of pathogenic mycoplasmas” Microbial Pathogenesis vol. 29: p. 301-309.
Damy et al,. “Coinfection of laboratory rats with Mycoplasma pulmonis and Chlamydia pneumoniae,” Contemp. Top.Am.Assoc.Lab.An.Sci. 42: 52-56 (2003).
Danesch, et al., 1997, “Chronic infections and coronary artery disease: is there a link?” Lancet, vol. 350: p. 430-436.
Fagundes RQ. Study of co-participation of natural infection by Chlamydophila pneumoniae and Mycoplasma pneumoniae in experimental atherogenesis in rabbits. Doctoral thesis presented at the Heart Institute of Clinical Hospitial, in the Cardiology Sciences Post Graduation Program of São Paulo University School of Medicine, Mar. 17, 2006. (The Summary is in the English language).
Farraji, et al., 1997, “Mycoplasma-associated pericarditis,” Mayo Clin. Proc., vol. 72: p. 33-36.
Fearon et al., “Cancer cachexia,” Int. J. Cardiol 85: 73-81 (2002).
Feng Shaw-Huey, et al., 1999, “Mycoplasma infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells,” Mol. Cel. Biol., vol. 19, No. 12: p. 7995-8002.
Florin THJ et al., “Shared and unique environmental factors determine the ecology of methanogens in humans and rats,” Am. J. Gastroenterol. 95: 2872-2879 (2000).
Fu et al., 1998, “Middle cerebral artery occlusion after recent Mycoplasma pneumoniae infection,” J. Neurol. Sci., vol. 157: p. 113-115.
Gabridge and Taylor-Robinson, “Interaction of Mycoplasma pneumoniae with human lung fibroblasts: role of receptor sites,” Infect. Immun. 25:455-459 (1979).
Giles et al., “Androgenetic alopecia and prostate cancer: findings from an Australian case-control study,” Cancer Epidemiol. Biomarkers Prev 11: 549-553 (2002).
Glasgow and Hill, “Interactions of Mycoplasma gallisepticum with sialyl glycoproteins,” Infect. Immun. 30:353-361 (1980).
Gurfinkel, et al., 1997, “IgG antibodies to chlamydial and mycoplasma infection plus C-reactive protein related to poor outcome in unstable angina,” Arch. Inst. Cardiol. Mex., vol. 67: p. 462-468.
Hansen, et
Baker & Botts LLP
Monshipouri Maryam
LandOfFree
Compositions for inhibiting atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for inhibiting atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for inhibiting atherosclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734652